|
Name |
2,5,6,7-tetrahydro-3H-cyclopenta[c]pyridazin-3-one
|
Molecular Formula | C7H8N2O | |
IUPAC Name* |
2,5,6,7-tetrahydrocyclopenta[c]pyridazin-3-one
|
|
SMILES |
C1CC2=CC(=O)NN=C2C1
|
|
InChI |
InChI=1S/C7H8N2O/c10-7-4-5-2-1-3-6(5)8-9-7/h4H,1-3H2,(H,9,10)
|
|
InChIKey |
HZLVYABRXDPPSA-UHFFFAOYSA-N
|
|
Synonyms |
122001-78-9; 2,5,6,7-tetrahydro-3H-cyclopenta[c]pyridazin-3-one; 6,7-Dihydro-2H-cyclopenta[c]pyridazin-3(5H)-one; 6,7-Dihydro-5H-cyclopenta[c]pyridazin-3-ol; 2H,3H,5H,6H,7H-cyclopenta[c]pyridazin-3-one; 2,5,6,7-tetrahydrocyclopenta[c]pyridazin-3-one; 2,5,6,7-TETRAHYDRO-CYCLOPENTA[C]PYRIDAZIN-3-ONE; MFCD07757617; 3H-Cyclopenta[c]pyridazin-3-one, 2,5,6,7-tetrahydro-; SCHEMBL20092675; DTXSID40409432; ALBB-028380; ZINC4342676; STK785697; AKOS005621180; AKOS023410365; AS-30198; SY180609; CS-0075473; EN300-60243; F1967-2558; F8888-0981; Z935132918; 2,5,6,7-tetrahydro-3H-cyclopenta[c]pyridazin-3-one(SALTDATA: FREE)
|
|
CAS | 122001-78-9 | |
PubChem CID | 5200288 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 136.15 | ALogp: | -0.1 |
HBD: | 1 | HBA: | 2 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 41.5 | Aromatic Rings: | 2 |
Heavy Atoms: | 10 | QED Weighted: | 0.569 |
Caco-2 Permeability: | -4.654 | MDCK Permeability: | 0.00001580 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.449 |
Human Intestinal Absorption (HIA): | 0.011 | 20% Bioavailability (F20%): | 0.005 |
30% Bioavailability (F30%): | 0.386 |
Blood-Brain-Barrier Penetration (BBB): | 0.977 | Plasma Protein Binding (PPB): | 24.58% |
Volume Distribution (VD): | 0.953 | Fu: | 62.50% |
CYP1A2-inhibitor: | 0.101 | CYP1A2-substrate: | 0.831 |
CYP2C19-inhibitor: | 0.081 | CYP2C19-substrate: | 0.059 |
CYP2C9-inhibitor: | 0.029 | CYP2C9-substrate: | 0.907 |
CYP2D6-inhibitor: | 0.05 | CYP2D6-substrate: | 0.765 |
CYP3A4-inhibitor: | 0.01 | CYP3A4-substrate: | 0.112 |
Clearance (CL): | 4.599 | Half-life (T1/2): | 0.649 |
hERG Blockers: | 0.023 | Human Hepatotoxicity (H-HT): | 0.245 |
Drug-inuced Liver Injury (DILI): | 0.654 | AMES Toxicity: | 0.118 |
Rat Oral Acute Toxicity: | 0.125 | Maximum Recommended Daily Dose: | 0.595 |
Skin Sensitization: | 0.145 | Carcinogencity: | 0.261 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.617 |
Respiratory Toxicity: | 0.437 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000345 | 0.273 | D0E6YQ | 0.217 | ||||
ENC000518 | 0.245 | D05IHU | 0.213 | ||||
ENC000393 | 0.231 | D00EEL | 0.208 | ||||
ENC003872 | 0.225 | D01JMC | 0.200 | ||||
ENC000450 | 0.225 | D00ETS | 0.190 | ||||
ENC000038 | 0.220 | D0V1UW | 0.184 | ||||
ENC000476 | 0.220 | D04KYY | 0.184 | ||||
ENC000753 | 0.217 | D07GRH | 0.183 | ||||
ENC003715 | 0.216 | D0N8DP | 0.182 | ||||
ENC003479 | 0.212 | D00MIN | 0.180 |